Skip to main content
. Author manuscript; available in PMC: 2016 Nov 20.
Published in final edited form as: Psychol Med. 2016 Feb 12;46(7):1459–1472. doi: 10.1017/S0033291716000064

Fig. 4.

Fig. 4

Risk ratio in treatment response (a) (≥50% reduction in Hamilton Depression Rating Scale/Montgomery–Åsberg Depression Rating Scale score) and remission (b) between non-ketamine N-methyl-D-aspartate receptor (NMDAR) antagonist-treated and placebo (PBO) control subjects in the articles analysed. Squares are effect sizes of single studies, diamonds of pooled results. CI, Confidence interval.